Relevant bibliographies by topics / Nucleic acid drug / Journal articles
To see the other types of publications on this topic, follow the link: Nucleic acid drug.

Journal articles on the topic 'Nucleic acid drug'

Author: Grafiati
Published: 4 June 2021
Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Nucleic acid drug.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Veal, James M. "Nucleic acid targeted drug design." Trends in Pharmacological Sciences 14, no. 10 (October 1993): 385–86. http://dx.doi.org/10.1016/0165-6147(93)90099-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Waring, Michael J. "Nucleic acid targeted drug design." Trends in Biotechnology 12, no. 1 (January 1994): 33. http://dx.doi.org/10.1016/0167-7799(94)90009-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tan, Xuyu, Fei Jia, Ping Wang, and Ke Zhang. "Nucleic acid-based drug delivery strategies." Journal of Controlled Release 323 (July 2020): 240–52. http://dx.doi.org/10.1016/j.jconrel.2020.03.040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ma, Z., and J. S. Taylor. "Nucleic acid-triggered catalytic drug release." Proceedings of the National Academy of Sciences 97, no. 21 (October 10, 2000): 11159–63. http://dx.doi.org/10.1073/pnas.97.21.11159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Takakura, Yoshinobu. "Nucleic Acid Drug Delivery and Targeting." Pharmaceutical Research 28, no. 4 (February 24, 2011): 691–93. http://dx.doi.org/10.1007/s11095-011-0394-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ashrafuzzaman, Md. "Aptamers as Both Drugs and Drug-Carriers." BioMed Research International 2014 (2014): 1–21. http://dx.doi.org/10.1155/2014/697923.

Full text
Abstract:
Aptamers are short nucleic acid oligos. They may serve as both drugs and drug-carriers. Their use as diagnostic tools is also evident. They can be generated using various experimental, theoretical, and computational techniques. The systematic evolution of ligands by exponential enrichment which uses iterative screening of nucleic acid libraries is a popular experimental technique. Theory inspired methodology entropy-based seed-and-grow strategy that designs aptamer templates to bind specifically to targets is another one. Aptamers are predicted to be highly useful in producing general drugs and theranostic drugs occasionally for certain diseases like cancer, Alzheimer’s disease, and so on. They bind to various targets like lipids, nucleic acids, proteins, small organic compounds, and even entire organisms. Aptamers may also serve as drug-carriers or nanoparticles helping drugs to get released in specific target regions. Due to better target specific physical binding properties aptamers cause less off-target toxicity effects. Therefore, search for aptamer based drugs, drug-carriers, and even diagnostic tools is expanding fast. The biophysical properties in relation to the target specific binding phenomena of aptamers, energetics behind the aptamer transport of drugs, and the consequent biological implications will be discussed. This review will open up avenues leading to novel drug discovery and drug delivery.
APA, Harvard, Vancouver, ISO, and other styles
7

Sun, Yue, Lingxian Meng, Yuxin Zhang, Dan Zhao, and Yunfeng Lin. "The Application of Nucleic Acids and Nucleic Acid Materials in Antimicrobial Research." Current Stem Cell Research & Therapy 16, no. 1 (December 1, 2021): 66–73. http://dx.doi.org/10.2174/1574888x15666200521084417.

Full text
Abstract:
Due to the misuse of antibiotics, multiple drug-resistant pathogenic bacteria have increasingly emerged. This has increased the difficulty of treatment as these bacteria directly affect public health by diminishing the potency of existing antibiotics. Developing alternative therapeutic strategies is the urgent need to reduce the mortality and morbidity related to drug-resistant bacterial infections. In the past 10 to 20 years, nanomedicines have been widely studied and applied as an antibacterial agent. They have become a novel tool for fighting resistant bacteria. The most common innovative substances, metal and metal oxide nanoparticles (NPs), have been widely reported. Until recently, DNA nanostructures were used alone or functionalized with specific DNA sequences by many scholars for antimicrobial purposes which were alternatively selected as therapy for severe bacterial infections. These are a potential candidate for treatments and have a considerable role in killing antibiotic-resistant bacteria. This review involves the dimensions of multidrug resistance and the mechanism of bacteria developing drug resistance. The importance of this article is that we summarized the current study of nano-materials based on nucleic acids in antimicrobial use. Meanwhile, the current progress and the present obstacles for their antibacterial and therapeutic use and special function of stem cells in this field are also discussed.
APA, Harvard, Vancouver, ISO, and other styles
8

Dosio, Franco, Silvia Arpicco, Barbara Stella, and Elias Fattal. "Hyaluronic acid for anticancer drug and nucleic acid delivery." Advanced Drug Delivery Reviews 97 (February 2016): 204–36. http://dx.doi.org/10.1016/j.addr.2015.11.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Traykovska, Martina, Sjoerd Miedema, and Robert Penchovsky. "Clinical Trials of Functional Nucleic Acids." International Journal of Biomedical and Clinical Engineering 7, no. 2 (July 2018): 46–60. http://dx.doi.org/10.4018/ijbce.2018070104.

Full text
Abstract:
This chapter describes how functional nucleic acids, such as aptamers, antisense oligonucleotides (ASOs), small interfering (si) RNAs, and ribozymes are considered by some researchers as valuable tools to develop therapeutic agents. They have not been particularly fast in reaching the market as medicines, due to endogenous barriers to extracellular trafficking and cellular uptake of nucleic acids and their inherent instability when applied in vivo. However, research carried out by the nucleic acid engineering community and pharmaceutical companies to circumvent these obstacles has led to the approval of a few aptamers and ASOs as drugs. Nucleic acid therapeutics are usually administered locally to diseased tissue. The drug candidates currently in clinical trials commonly use the same administration methods as previously licensed nucleic acid therapeutics. These administration techniques carry their own safety risks and advantages. In this article, the present state is discussed and prospective options for the use ASOs and aptamers as drugs are listed.
APA, Harvard, Vancouver, ISO, and other styles
10

Mulvey, Matthew C., Margaret Lemmon, Stephanie Rotter, Jonathan Lees, Leo Einck, and Carol A. Nacy. "Optimization of a Nucleic Acid-Based Reporter System To Detect Mycobacterium tuberculosis Antibiotic Sensitivity." Antimicrobial Agents and Chemotherapy 59, no. 1 (November 3, 2014): 407–13. http://dx.doi.org/10.1128/aac.03135-14.

Full text
Abstract:
ABSTRACTWe previously reported the development of a prototype antibiotic sensitivity assay to detect drug-resistantMycobacterium tuberculosisusing infection by mycobacteriophage to create a novel nucleic acid transcript, a surrogate marker of mycobacterial viability, detected by reverse transcriptase PCR (M. C. Mulvey et al., mBio3:e00312-11, 2012). This assay detects antibiotic resistance to all drugs, even drugs for which the resistance mechanism is unknown or complex: it is a phenotypic readout using nucleic acid detection. In this report, we describe development and characteristics of an optimized reporter system that directed expression of the RNA cyclase ribozyme, which generated circular RNA through an intramolecular splicing reaction and led to accumulation of a new nucleic acid sequence in phage-infected bacteria. These modifications simplified the assay, increased the limit of detection from 104to <102M. tuberculosiscells, and correctly identified the susceptibility profile ofM. tuberculosisstrains exposed for 16 h to either first-line or second-line antitubercular drugs. In addition to phenotypic drug resistance or susceptibility, the assay reported streptomycin MICs and clearly detected 10% drug-resistant cells in an otherwise drug-susceptible population.
APA, Harvard, Vancouver, ISO, and other styles
11

Opalinska, Joanna. "Nucleic acid drugs in the clinic." Expert Opinion on Drug Discovery 2, no. 3 (March 2007): 321–33. http://dx.doi.org/10.1517/17460441.2.3.321.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Oyama, Shota, Tsuyoshi Yamamoto, and Asako Yamayoshi. "Recent Advances in the Delivery Carriers and Chemical Conjugation Strategies for Nucleic Acid Drugs." Cancers 13, no. 15 (August 1, 2021): 3881. http://dx.doi.org/10.3390/cancers13153881.

Full text
Abstract:
With the development of new anticancer medicines, novel modalities are being explored for cancer treatment. For many years, conventional modalities, such as small chemical drugs and antibody drugs, have worked by “inhibiting the function” of target proteins. In recent years, however, nucleic acid drugs, such as ASOs and siRNAs, have attracted attention as a new modality for cancer treatment because nucleic acid drugs can directly promote the “loss of function” of target genes. Recently, nucleic acid drugs for use in cancer therapy have been extensively developed and some of them have currently been under investigation in clinical trials. To develop novel nucleic acid drugs for cancer treatment, it is imperative that cancer researchers, including ourselves, cover and understand those latest findings. In this review, we introduce and provide an overview of various DDSs and ligand modification technologies that are being employed to improve the success and development of nucleic acid drugs, then we also discuss the future of nucleic acid drug developments for cancer therapy. It is our belief this review will increase the awareness of nucleic acid drugs worldwide and build momentum for the future development of new cancer-targeted versions of these drugs.
APA, Harvard, Vancouver, ISO, and other styles
13

Wu, Yuanbing, Ania Rashidpour, María Pilar Almajano, and Isidoro Metón. "Chitosan-Based Drug Delivery System: Applications in Fish Biotechnology." Polymers 12, no. 5 (May 21, 2020): 1177. http://dx.doi.org/10.3390/polym12051177.

Full text
Abstract:
Chitosan is increasingly used for safe nucleic acid delivery in gene therapy studies, due to well-known properties such as bioadhesion, low toxicity, biodegradability and biocompatibility. Furthermore, chitosan derivatization can be easily performed to improve the solubility and stability of chitosan–nucleic acid polyplexes, and enhance efficient target cell drug delivery, cell uptake, intracellular endosomal escape, unpacking and nuclear import of expression plasmids. As in other fields, chitosan is a promising drug delivery vector with great potential for the fish farming industry. This review highlights state-of-the-art assays using chitosan-based methodologies for delivering nucleic acids into cells, and focuses attention on recent advances in chitosan-mediated gene delivery for fish biotechnology applications. The efficiency of chitosan for gene therapy studies in fish biotechnology is discussed in fields such as fish vaccination against bacterial and viral infection, control of gonadal development and gene overexpression and silencing for overcoming metabolic limitations, such as dependence on protein-rich diets and the low glucose tolerance of farmed fish. Finally, challenges and perspectives on the future developments of chitosan-based gene delivery in fish are also discussed.
APA, Harvard, Vancouver, ISO, and other styles
14

Tan, Xuyu, Ben B. Li, Xueguang Lu, Fei Jia, Clarissa Santori, Priyanka Menon, Hui Li, Bohan Zhang, Jean J. Zhao, and Ke Zhang. "Light-Triggered, Self-Immolative Nucleic Acid-Drug Nanostructures." Journal of the American Chemical Society 137, no. 19 (May 7, 2015): 6112–15. http://dx.doi.org/10.1021/jacs.5b00795.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Awino, Joseph K., Saketh Gudipati, Alyssa K. Hartmann, Joshua J. Santiana, Dominic F. Cairns-Gibson, Nicole Gomez, and Jessica L. Rouge. "Nucleic Acid Nanocapsules for Enzyme-Triggered Drug Release." Journal of the American Chemical Society 139, no. 18 (April 25, 2017): 6278–81. http://dx.doi.org/10.1021/jacs.6b13087.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Li, Yulin, Dina Maciel, João Rodrigues, Xiangyang Shi, and Helena Tomás. "Biodegradable Polymer Nanogels for Drug/Nucleic Acid Delivery." Chemical Reviews 115, no. 16 (August 11, 2015): 8564–608. http://dx.doi.org/10.1021/cr500131f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

de Vries, Jan Willem, Feng Zhang, and Andreas Herrmann. "Drug delivery systems based on nucleic acid nanostructures." Journal of Controlled Release 172, no. 2 (December 2013): 467–83. http://dx.doi.org/10.1016/j.jconrel.2013.05.022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Hida, Kaoru, Justin Hanes, and Marc Ostermeier. "Directed evolution for drug and nucleic acid delivery." Advanced Drug Delivery Reviews 59, no. 15 (December 2007): 1562–78. http://dx.doi.org/10.1016/j.addr.2007.08.022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Hagedorn, Peter H., Robert Persson, Erik D. Funder, Nanna Albæk, Sanna L. Diemer, Dennis J. Hansen, Marianne R. Møller, et al. "Locked nucleic acid: modality, diversity, and drug discovery." Drug Discovery Today 23, no. 1 (January 2018): 101–14. http://dx.doi.org/10.1016/j.drudis.2017.09.018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

SUZUKI, Jun-ichi. "The 2nd Seminar for Nucleic Acid Drugs and Drug Delivery System." Hosokawa Powder Technology Foundation ANNUAL REPORT 25 (2017): 181–82. http://dx.doi.org/10.14356/hptf.16001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Godeshala, Sudhakar, Bhavani Miryala, Subhadeep Dutta, Matthew D. Christensen, Purbasha Nandi, Po-Lin Chiu, and Kaushal Rege. "A library of aminoglycoside-derived lipopolymer nanoparticles for delivery of small molecules and nucleic acids." Journal of Materials Chemistry B 8, no. 37 (2020): 8558–72. http://dx.doi.org/10.1039/d0tb00924e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Buhmann, Raymund, Ting Yang, Monica Schifferer, Martin Obermeier, Gundula Jaeger, and Hans-Jochem Kolb. "Therapeutic Nucleic Acids: A Potential Source of Resistance to Cancer, Antiviral and Immunosuppressive Therapy." Blood 112, no. 11 (November 16, 2008): 1614. http://dx.doi.org/10.1182/blood.v112.11.1614.1614.

Full text
Abstract:
Abstract According to their unique structural and chemical properties nucleic acids were recognized to provide inherent therapeutic potential beyond sole information storage. In the meantime an increasing number of nucleic acid based drugs achieved FDA approval and entered clinical trails (e.g. “antisense” or “immunosustimulatory CpG” oligodeoxynucletides (ODNs), aptamers, ribozymes, RNA interference or defibrotide). But so far, no or less information is available whether these compounds might compete with chemically and structurally related drugs, e.g. nucleoside analogues (NA) widely used in cancer or antiviral therapy, or interfere with the intracellular nucleic acid metabolism. In the present report we provide evidence, that nucleic-acid based drugs antagonize fludarabine, acyclovir or mycophenolate mofetil (MMF). In presence of defibrotide (DF), a polydisperse mixture of single-stranded oligodeoxyribonucleotides (15 to 30 kD) e.g. used for treatment of hepatic veno-occlusive disease and other endothelial disorders, fludarabine treated lymphocytes or myeloid blasts where rescued from apoptosis. According to nucleic acid degradation the resulting metabolite deoxycytidine turned out to be the key substrate competing with fludarabine for phosphorylation by deoxycitidine kinase (dCK) and suggested interference with nucleic acid metabolism rather than direct competition with the drug for cellular uptake. Moreover, in standard drug resistance assays using acyclovir sensitive herpes simplex virus (HSV) strains (V0631508), 4 mM of DF restored viral replication in presence of 50 mM acyclovir. This was confirmed by quantitative PCR of viral DNA. Here, deoxythymidine turned out to be the main competitor for intracellular phosphorylation mediated by virus thymidine kinase. To further extent our findings, that an increase of the extracellular concentration of nucleic acids directly interfere with the intracellular nucleic acid metabolism, mixed lymphocyte reactions (MLRs) were performed, to test whether the immunosuppressive effects of mycophenolate mofetil (MMF) could be reversed. As control cyclosporine A (CsA) was used. Here, addition of singular ribonucleotides almost completely antagonized the T cell inhibitory effects of mycophenolic acid (MPA), respectively its prodrug MMF, but not of CsA. As MPA is known to be a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, a key enzyme for the de novo pathway of guanosine nucleotide synthesis, addition of guanosine to the MLRs was found to be effective and sufficient to reverse the immunosuppressive effects of MPA. We conclude that treatment with nucleic-acid-based drugs interfere with the intracellular nucleic acid metabolism, thus decreasing the efficacy of NAs used for cancer and antiviral therapy or the immunosuppressive therapy using MMF. Prospective clinical trials are required to confirm these in vitro findings.
APA, Harvard, Vancouver, ISO, and other styles
23

Campuzano, Susana, María Pedrero, and José M. Pingarrón. "Electrochemical Nucleic Acid-Based Biosensing of Drugs of Abuse and Pharmaceuticals." Current Medicinal Chemistry 25, no. 33 (October 24, 2018): 4102–18. http://dx.doi.org/10.2174/0929867324666171121103156.

Full text
Abstract:
Background: Studies on the interactions of DNA with small molecular drugs are currently performed both to explore their mechanism of action and to develop new drugs. Electrochemical biosensors offer a very promising alternative to more complex conventional techniques for drug determination due to rapidness, low cost, simplicity, high sensitivity and compatibility with use in different settings. In this review, selected electrochemical nucleic acid-based biosensing methods described so far for the determination of pharmaceuticals and illicit drugs are briefly overviewed, discussing their basics and main features. A section pointing out general conclusions and future directions in this field is also provided. Results: The 42 selected contributions described electrochemical platforms to determine drugs of interest by monitoring their specific interactions with nucleic acids (DNA and aptamers), DNA damage and specific DNA-protein interactions. The highlighted approaches reported the use of electrodes unmodified or modified with nanomaterials and/or polymers in which DNA-drug interaction was followed by electrochemical detection of DNA puric bases, active drug or diffusion-free markers, and monitoring changes in the surface layer morphology/permeability and charge transfer resistance using different electrochemical techniques. Conclusion: Although electrochemical nucleic acid biosensing approaches constitute an interesting option for drugs determination in terms of cost, simplicity and miniaturized instrumentation, validating exhaustively their performance in real samples against conventional methodologies and implementing them into portable and automatic high throughput devices, together with exploring novel electrode modifications with nanomaterials and polymers and studying in more detail their multiplexing ability for analysis of a large number of analytes, is still needed.
APA, Harvard, Vancouver, ISO, and other styles
24

Buhmann, Raymund, Ting Yang, Martin Obermeier, Gundula Jaeger, and Hans-Jochem Kolb. "Exogenous Nucleic Acids - A Potential Source of Resistance to Nucleoside Analogues in Cancer and Antiviral Therapy." Blood 110, no. 11 (November 16, 2007): 4207. http://dx.doi.org/10.1182/blood.v110.11.4207.4207.

Full text
Abstract:
Abstract The metabolism of exogenous nucleic acids is not well defined. Moreover, there is little information whether there might be interference with chemically and structurally related drugs, e.g. nucleoside analogues (NA) widely used in cancer or in antiviral therapy. In the present report we provide evidence, that nucleic-acid based drugs might antagonize fludarabine or acyclovir. In vitro, fludarabine treated lymphocytes or myeloid blasts where rescued from apoptosis when incubated with defibrotide (DF), a polydisperse mixture of single-stranded oligodeoxyribonucleotides (15 to 30 kD) or singular deoxynucleotides. Thereby deoxycytidine (dCTP) turned out to be the key substrate competing with fludarabine for phosphorylation by deoxycitidine kinase (dCK) and suggested interference with nucleic acid metabolism rather than direct competition with the drug. To further prove this hypothesis the influence of defibrotide on HSV replication was evaluated. In standard drug resistance assays performed with acyclovir sensitive herpes simplex virus (HSV) strains (V0631508) 4 mM of DF restored viral replication in presence of 50 mM acyclovir. This was confirmed by quantitative PCR of viral DNA. Moreover, in this case deoxythymidine (dTTP) turned out to be the competitor for intracellular phosphorylation mediated by virus thymidine kinase. We conclude that treatment with DF and other nucleic-acid-based drugs interfere with the efficacy of NA used for cancer and antiviral therapy. Prospective clinical trials are required to confirm these in vitro findings.
APA, Harvard, Vancouver, ISO, and other styles
25

Obuobi, Sybil, and Nataša Škalko-Basnet. "Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers." Pharmaceutics 12, no. 7 (July 8, 2020): 643. http://dx.doi.org/10.3390/pharmaceutics12070643.

Full text
Abstract:
Conventional antibiotic therapy is often challenged by poor drug penetration/accumulation at infection sites and poses a significant burden to public health. Effective strategies to enhance the therapeutic efficacy of our existing arsenal include the use of nanoparticulate delivery platforms to improve drug targeting and minimize adverse effects. However, these nanocarriers are often challenged by poor loading efficiency, rapid release and inefficient targeting. Nucleic acid hybrid nanocarriers are nucleic acid nanosystems complexed or functionalized with organic or inorganic materials. Despite their immense potential in antimicrobial therapy, they are seldom utilized against pathogenic bacteria. With the emergence of antimicrobial resistance and the associated complex interplay of factors involved in antibiotic resistance, nucleic acid hybrids represent a unique opportunity to deliver antimicrobials against resistant pathogens and to target specific genes that control virulence or resistance. This review provides an unbiased overview on fabricating strategies for nucleic acid hybrids and addresses the challenges of pristine oligonucleotide nanocarriers. We report recent applications to enhance pathogen targeting, binding and control drug release. As multifunctional next-generational antimicrobials, the challenges and prospect of these nanocarriers are included.
APA, Harvard, Vancouver, ISO, and other styles
26

Ma, Yuan, Hongxia Liu, Quanbing Mou, Deyue Yan, Xinyuan Zhu, and Chuan Zhang. "Floxuridine-containing nucleic acid nanogels for anticancer drug delivery." Nanoscale 10, no. 18 (2018): 8367–71. http://dx.doi.org/10.1039/c8nr01226a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Gan, JianHua, Jia Sheng, and Zhen Huang. "Chemical and structural biology of nucleic acids and protein-nucleic acid complexes for novel drug discovery." Science China Chemistry 54, no. 1 (January 2011): 3–23. http://dx.doi.org/10.1007/s11426-010-4174-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Santosh, Baby, and Pramod K. Yadava. "Nucleic Acid Aptamers: Research Tools in Disease Diagnostics and Therapeutics." BioMed Research International 2014 (2014): 1–13. http://dx.doi.org/10.1155/2014/540451.

Full text
Abstract:
Aptamers are short sequences of nucleic acid (DNA or RNA) or peptide molecules which adopt a conformation and bind cognate ligands with high affinity and specificity in a manner akin to antibody-antigen interactions. It has been globally acknowledged that aptamers promise a plethora of diagnostic and therapeutic applications. Although use of nucleic acid aptamers as targeted therapeutics or mediators of targeted drug delivery is a relatively new avenue of research, one aptamer-based drug “Macugen” is FDA approved and a series of aptamer-based drugs are in clinical pipelines. The present review discusses the aspects of design, unique properties, applications, and development of different aptamers to aid in cancer diagnosis, prevention, and/or treatment under defined conditions.
APA, Harvard, Vancouver, ISO, and other styles
29

Kolář, Michal H., and Oriana Tabarrini. "Halogen Bonding in Nucleic Acid Complexes." Journal of Medicinal Chemistry 60, no. 21 (June 23, 2017): 8681–90. http://dx.doi.org/10.1021/acs.jmedchem.7b00329.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Sun, Zhi-Yin, Xiao-Na Wang, Sui-Qi Cheng, Xiao-Xuan Su, and Tian-Miao Ou. "Developing Novel G-Quadruplex Ligands: from Interaction with Nucleic Acids to Interfering with Nucleic Acid–Protein Interaction." Molecules 24, no. 3 (January 22, 2019): 396. http://dx.doi.org/10.3390/molecules24030396.

Full text
Abstract:
G-quadruplex is a special secondary structure of nucleic acids in guanine-rich sequences of genome. G-quadruplexes have been proved to be involved in the regulation of replication, DNA damage repair, and transcription and translation of oncogenes or other cancer-related genes. Therefore, targeting G-quadruplexes has become a novel promising anti-tumor strategy. Different kinds of small molecules targeting the G-quadruplexes have been designed, synthesized, and identified as potential anti-tumor agents, including molecules directly bind to the G-quadruplex and molecules interfering with the binding between the G-quadruplex structures and related binding proteins. This review will explore the feasibility of G-quadruplex ligands acting as anti-tumor drugs, from basis to application. Meanwhile, since helicase is the most well-defined G-quadruplex-related protein, the most extensive research on the relationship between helicase and G-quadruplexes, and its meaning in drug design, is emphasized.
APA, Harvard, Vancouver, ISO, and other styles
31

Sun, Lun Quan, and Jonathan P. Wong. "Frontiers in nucleic acid-based drug research and development." Future Medicinal Chemistry 7, no. 13 (September 2015): 1619–21. http://dx.doi.org/10.4155/fmc.15.117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Bacher, Jamie M., and Andrew D. Ellington. "Nucleic acid selection as a tool for drug discovery." Drug Discovery Today 3, no. 6 (June 1998): 265–73. http://dx.doi.org/10.1016/s1359-6446(97)01166-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Booth, David E., and Kidong Lee. "Robust regression-based analysis of drug–nucleic acid binding." Analytical Biochemistry 319, no. 2 (August 2003): 258–62. http://dx.doi.org/10.1016/s0003-2697(03)00290-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Sakaue, Saori, and Yukinori Okada. "Statistical Genetics Contributes to the Nucleic Acid Drug Discovery." Nihon Naika Gakkai Zasshi 109, no. 1 (January 10, 2020): 107–12. http://dx.doi.org/10.2169/naika.109.107.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Holt, Patrick A., Robert Buscaglia, John O. Trent, and Jonathan B. Chaires. "A discovery funnel for nucleic acid binding drug candidates." Drug Development Research 72, no. 2 (December 16, 2010): 178–86. http://dx.doi.org/10.1002/ddr.20414.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Sakaue, Saori, and Yukinori Okada. "Statistical Genetics Contributes to the Nucleic Acid Drug Discovery." Nihon Naika Gakkai Zasshi 109, no. 1 (January 10, 2020): 107–12. http://dx.doi.org/10.2169/naika.109.107.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Cerasi, Aurora, Enrico Millo, Maria Francesca Ottaviani, Gianluca Damonte, Michela Cangiotti, Umberto Benatti, and Laura Chiarantini. "New synthesis of a spin-labeled peptide nucleic acid and its interactions with nucleic acids." Tetrahedron Letters 44, no. 48 (November 2003): 8701–4. http://dx.doi.org/10.1016/j.tetlet.2003.09.150.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Yilancioglu. "Antimicrobial Drug Interactions: Systematic Evaluation of Protein and Nucleic Acid Synthesis Inhibitors." Antibiotics 8, no. 3 (August 9, 2019): 114. http://dx.doi.org/10.3390/antibiotics8030114.

Full text
Abstract:
Antimicrobial multidrug resistance and its transmission among strains are serious problems. Success rate is decreased and treatment options are narrowed due to increasing bacterial multidrug resistance. On the other hand, the need for long-term efforts to discover new antibiotics and difficulties finding new treatment protocols make this problem more complex. Combination therapy, especially with synergistic use of antimicrobials is a rational treatment option with huge benefits. Thus, screening antibiotic interactions is crucial for finding better treatment options. Clinicians currently use combinatorial antibiotic treatment as an effective treatment option. However, antibiotics can show synergistic or antagonistic interactions when used together. In our study, we aimed to investigate interactions of antibiotics with different mechanisms of action. Antibiotics, which act as protein synthesis inhibitors (P) and nucleic acid synthesis inhibitors (N) were used in our study. We tested 66 (PN), 15 (NN), and 55 (PP) drug pairs on the Escherichia coli strain. The Loewe additivity model was used and alpha scores were calculated for analysis of interactions of drug combinations. Drug interactions were categorized as synergistic or antagonistic. Accordingly, pairwise combinations of protein synthesis inhibitors (PP) showed stronger synergistic interactions than those of nucleic acid synthesis inhibitors (NN) and nucleic acid synthesis–protein synthesis inhibitors (PN). As a result, the importance of mechanisms of action of drugs is emphasized in the selection of synergistic drug combinations.
APA, Harvard, Vancouver, ISO, and other styles
39

Slivac, Igor, David Guay, Mathias Mangion, Juliette Champeil, and Bruno Gaillet. "Non-viral nucleic acid delivery methods." Expert Opinion on Biological Therapy 17, no. 1 (November 9, 2016): 105–18. http://dx.doi.org/10.1080/14712598.2017.1248941.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Lamberti, Gaetano, and Anna Angela Barba. "Drug Delivery of siRNA Therapeutics." Pharmaceutics 12, no. 2 (February 20, 2020): 178. http://dx.doi.org/10.3390/pharmaceutics12020178.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Karlsen, Kasper K., and Jesper Wengel. "Locked Nucleic Acid and Aptamers." Nucleic Acid Therapeutics 22, no. 6 (December 2012): 366–70. http://dx.doi.org/10.1089/nat.2012.0382.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Wiraja, Christian, David C. Yeo, and Chenjie Xu. "Framework Nucleic Acids: A Paradigm Shift in Transdermal Drug Delivery." SLAS TECHNOLOGY: Translating Life Sciences Innovation 24, no. 5 (May 23, 2019): 531–32. http://dx.doi.org/10.1177/2472630319848679.

Full text
Abstract:
Transdermal drug delivery (TDD) provides a direct drug administration route bypassing gastrointestinal and liver metabolism. Until now, topical nanocarriers responsible for efficient TDD are predominantly polymeric or lipid based. The size-dependent skin penetration ability of framework nucleic acids (FNAs) has recently been reported, along with their efficacy in delivering doxorubicin for skin melanoma therapy. This commentary is to highlight the paradigm shift of nucleic acid delivery from being a cargo moiety to serving as a drug carrier instead. Further development directions to maximize the potential of FNAs for TDD are also discussed.
APA, Harvard, Vancouver, ISO, and other styles
43

Subjakova, Veronika, Veronika Oravczova, and Tibor Hianik. "Polymer Nanoparticles and Nanomotors Modified by DNA/RNA Aptamers and Antibodies in Targeted Therapy of Cancer." Polymers 13, no. 3 (January 21, 2021): 341. http://dx.doi.org/10.3390/polym13030341.

Full text
Abstract:
Polymer nanoparticles and nano/micromotors are novel nanostructures that are of increased interest especially in the diagnosis and therapy of cancer. These structures are modified by antibodies or nucleic acid aptamers and can recognize the cancer markers at the membrane of the cancer cells or in the intracellular side. They can serve as a cargo for targeted transport of drugs or nucleic acids in chemo- immuno- or gene therapy. The various mechanisms, such as enzyme, ultrasound, magnetic, electrical, or light, served as a driving force for nano/micromotors, allowing their transport into the cells. This review is focused on the recent achievements in the development of polymer nanoparticles and nano/micromotors modified by antibodies and nucleic acid aptamers. The methods of preparation of polymer nanoparticles, their structure and properties are provided together with those for synthesis and the application of nano/micromotors. The various mechanisms of the driving of nano/micromotors such as chemical, light, ultrasound, electric and magnetic fields are explained. The targeting drug delivery is based on the modification of nanostructures by receptors such as nucleic acid aptamers and antibodies. Special focus is therefore on the method of selection aptamers for recognition cancer markers as well as on the comparison of the properties of nucleic acid aptamers and antibodies. The methods of immobilization of aptamers at the nanoparticles and nano/micromotors are provided. Examples of applications of polymer nanoparticles and nano/micromotors in targeted delivery and in controlled drug release are presented. The future perspectives of biomimetic nanostructures in personalized nanomedicine are also discussed.
APA, Harvard, Vancouver, ISO, and other styles
44

Koo, Bonwoo, Haneul Yoo, Ho Jeong Choi, Min Kim, Cheoljae Kim, and Ki Tae Kim. "Visible Light Photochemical Reactions for Nucleic Acid-Based Technologies." Molecules 26, no. 3 (January 21, 2021): 556. http://dx.doi.org/10.3390/molecules26030556.

Full text
Abstract:
The expanding scope of chemical reactions applied to nucleic acids has diversified the design of nucleic acid-based technologies that are essential to medicinal chemistry and chemical biology. Among chemical reactions, visible light photochemical reaction is considered a promising tool that can be used for the manipulations of nucleic acids owing to its advantages, such as mild reaction conditions and ease of the reaction process. Of late, inspired by the development of visible light-absorbing molecules and photocatalysts, visible light-driven photochemical reactions have been used to conduct various molecular manipulations, such as the cleavage or ligation of nucleic acids and other molecules as well as the synthesis of functional molecules. In this review, we describe the recent developments (from 2010) in visible light photochemical reactions involving nucleic acids and their applications in the design of nucleic acid-based technologies including DNA photocleaving, DNA photoligation, nucleic acid sensors, the release of functional molecules, and DNA-encoded libraries.
APA, Harvard, Vancouver, ISO, and other styles
45

Uemachi, Hiro, Yuuya Kasahara, Keisuke Tanaka, Takumi Okuda, Yoshihiro Yoneda, and Satoshi Obika. "Hybrid-Type SELEX for the Selection of Artificial Nucleic Acid Aptamers Exhibiting Cell Internalization Activity." Pharmaceutics 13, no. 6 (June 15, 2021): 888. http://dx.doi.org/10.3390/pharmaceutics13060888.

Full text
Abstract:
Nucleic acid aptamers have attracted considerable attention as next-generation pharmaceutical agents and delivery vehicles for small molecule drugs and therapeutic oligonucleotides. Chemical modification is an effective approach for improving the functionality of aptamers. However, the process of selecting appropriately modified aptamers is laborious because of many possible modification patterns. Here, we describe a hybrid-type systematic evolution of ligands by exponential enrichment (SELEX) approach for the generation of the artificial nucleic acid aptamers effective against human TROP2, a cell surface protein identified by drug discovery as a promising target for cancer therapy. Capillary electrophoresis SELEX was used for the pre-screening of multiple modified nucleic acid libraries and enrichment of TROP2 binding aptamers in the first step, followed by functional screening using cell-SELEX in the second step for the generation of cell-internalizing aptamers. One representative aptamer, Tac-B1, had a nanomolar-level affinity to human TROP2 and exhibited elevated capacity for internalization by cells. Because of the growing interest in the application of aptamers for drug delivery, our hybrid selection approach has great potential for the generation of functional artificial nucleic acid aptamers with ideal modification patterns in vitro.
APA, Harvard, Vancouver, ISO, and other styles
46

Hari, Yvonne, Adrien Nyakas, Silvan R. Stucki, and Stefan Schürch. "Elucidation of Nucleic Acid–Drug Interactions by Tandem Mass Spectrometry." CHIMIA International Journal for Chemistry 68, no. 3 (March 26, 2014): 164–67. http://dx.doi.org/10.2533/chimia.2014.164.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Ellington, Andrew D. "Using in vitro nucleic acid selections for conventional drug design." Drug Development Research 33, no. 2 (October 1994): 102–15. http://dx.doi.org/10.1002/ddr.430330207.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Seaman, Frederick C., and Laurence H. Hurley. "31P-Nmr as a Probe for Drug-Nucleic Acid Interactions." Phosphorus, Sulfur, and Silicon and the Related Elements 144, no. 1 (January 1, 1999): 297–300. http://dx.doi.org/10.1080/10426509908546240.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Iyer, Arun K., Zhenfeng Duan, and Mansoor M. Amiji. "Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors." Molecular Pharmaceutics 11, no. 8 (April 2014): 2511–26. http://dx.doi.org/10.1021/mp500024p.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Gautherot, Isabelle, and Reg??s Sodoyer. "A Multi-Model Approach to Nucleic Acid-Based Drug Development." BioDrugs 18, no. 1 (2004): 37–50. http://dx.doi.org/10.2165/00063030-200418010-00004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Nucleic acid drug' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography